Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqGS - Delayed Quote USD

Assembly Biosciences, Inc. (ASMB)

Compare
8.71
-0.60
(-6.44%)
At close: April 4 at 4:00:03 PM EDT
8.70
-0.01
(-0.11%)
After hours: April 4 at 7:15:57 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for ASMB

Recent News: ASMB

View More
Assembly Biosciences (ASMB) Upgraded to Buy: What Does It Mean for the Stock?

Assembly Biosciences (ASMB) Upgraded to Buy: What Does It Mean for the Stock?
Zacks 9 days ago
Assembly Biosciences Full Year 2024 Earnings: Beats Expectations

Assembly Biosciences Full Year 2024 Earnings: Beats Expectations
Simply Wall St. 14 days ago
Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights

Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights
GlobeNewswire 15 days ago
Assembly Biosciences Insiders Placed Bullish Bets Worth US$679.4k

Assembly Biosciences Insiders Placed Bullish Bets Worth US$679.4k
Simply Wall St. 17 days ago
Is Assembly Biosciences, Inc. (ASMB) Among Stocks With At Least $20 Million In Insider Spending Recently?

Is Assembly Biosciences, Inc. (ASMB) Among Stocks With At Least $20 Million In Insider Spending Recently?
Insider Monkey last month
Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
GlobeNewswire last month
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes

Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes
GlobeNewswire last month
Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B
GlobeNewswire 3 months ago
Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs

Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs
GlobeNewswire 3 months ago
Bearish: Analysts Just Cut Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Revenue and EPS estimates

Bearish: Analysts Just Cut Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Revenue and EPS estimates
Simply Wall St. 4 months ago

Assembly Biosciences: Q3 Earnings Snapshot
Associated Press Finance 4 months ago
View More

Related Tickers

SPRO Spero Therapeutics, Inc.
0.5820
-6.73%
 
HLVX HilleVax, Inc.
1.4200
-2.07%
 
KROS Keros Therapeutics, Inc.
9.98
-2.92%
 
CLRB Cellectar Biosciences, Inc.
0.2644
-9.82%
 
GLTO Galecto, Inc.
2.5400
-11.19%
 
NXTC NextCure, Inc.
0.3901
-1.74%
 
EPIX ESSA Pharma Inc.
1.4800
-6.33%
 
THRD Third Harmonic Bio, Inc.
3.4800
-2.52%
 
VTYX Ventyx Biosciences, Inc.
0.9398
-6.02%
 
PMVP PMV Pharmaceuticals, Inc.
1.0000
+0.50%